METTL14 and metabolic disease: Recent studies have identified that METTL14/m6A-mediated epitranscriptomic alterations disrupt ADRB signaling in adipose tissue, contributing to the development of obesity, NAFLD, and other metabolic disorders (Kang et al., 2023).